Humacyte, Inc. (HUMAW) — SEC Filings
Humacyte, Inc. (HUMAW) — 42 SEC filings. Latest: 8-K (Dec 16, 2025). Includes 24 8-K, 6 10-Q, 6 SC 13D/A.
View Humacyte, Inc. on SEC EDGAR
Overview
Humacyte, Inc. (HUMAW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 16, 2025: On December 16, 2025, Humacyte, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statements and exhibits. Humacyte, Inc. is a biotechnology company focused on biological products.
Sentiment Summary
Across 42 filings, the sentiment breakdown is: 2 bearish, 38 neutral, 2 mixed. The dominant filing sentiment for Humacyte, Inc. is neutral.
Filing Type Overview
Humacyte, Inc. (HUMAW) has filed 24 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13D/A, 2 SC 13G with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (42)
Risk Profile
Risk Assessment: Of HUMAW's 39 recent filings, 4 were flagged as high-risk, 19 as medium-risk, and 16 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1.6 million |
| Net Income | -$16.0 million |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $19.5 million |
| Operating Margin | N/A |
| Total Assets | $91.5 million |
| Total Debt | $96.3 million |
Key Executives
- Laura E. Niklason
- Brady W. Dougan
- John P. Bamforth
- Emery N. Brown
- Michael T. Constantino
- Keith Anthony Jones
- Susan Windham-Bannister
Industry Context
Humacyte operates in the regenerative medicine and biotechnology sector, focusing on developing bioengineered human tissues. This industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Success hinges on clinical trial outcomes, regulatory approvals, and eventual market adoption, often facing competition from established pharmaceutical companies and other innovative biotech firms.
Top Tags
sec-filing (6) · corporate-filing (5) · material-definitive-agreement (5) · 8-k (4) · company-update (4) · financial-reporting (4) · Biotechnology (3) · biotech (3) · corporate-action (3) · 10-Q (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $17.5M | Reduced from $39.2M in Q3 2024, a 55% improvement. |
| Net Loss (YTD 2025) | $16.0M | Significantly down from $127.8M in YTD 2024, an 87% improvement. |
| Total Revenue (YTD 2025) | $1.6M | First reported revenue, including $950K product revenue and $621K contract revenue. |
| Accumulated Deficit | $702.0M | Increased from $686.0M at December 31, 2024, indicating continued losses. |
| Net Cash Used in Operations (YTD 2025) | $78.9M | Increased from $71.5M in YTD 2024, showing higher cash burn. |
| Cash and Cash Equivalents | $19.5M | Decreased from $44.9M at December 31, 2024, indicating declining liquidity. |
| Revenue Interest Repayment | $50.0M | Made on September 17, 2025, reducing liability but depleting restricted cash. |
| R&D Expenses (YTD 2025) | $54.7M | Decreased from $67.9M in YTD 2024, a 19.5% reduction. |
| Change in Fair Value of Contingent Earnout Liability (YTD 2025) | $49.2M | Positive change significantly offset net loss, compared to a negative $38.7M in YTD 2024. |
| Common Shares Outstanding | 158,835,303 | Increased from 130,027,509 at December 31, 2024, indicating dilution. |
| Product Revenue | $0 | for the three and six months ended June 30, 2025, indicating pre-commercialization stage. |
| Total Revenue | $0 | for the three and six months ended June 30, 2025, consistent with prior year. |
| Revenue | $0.16M | Q1 2025 revenue was $0.16 million, same as Q1 2024. |
| Operating Expenses | $16.4M | Q1 2025 operating expenses were $16.4 million, same as Q1 2024. |
| Fiscal Year End | 2024 | Reporting period for the 10-K |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Humacyte, Inc. (HUMAW)?
Humacyte, Inc. has 42 recent SEC filings from Feb 2024 to Dec 2025, including 24 8-K, 6 10-Q, 6 SC 13D/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of HUMAW filings?
Across 42 filings, the sentiment breakdown is: 2 bearish, 38 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Humacyte, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Humacyte, Inc. (HUMAW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Humacyte, Inc.?
Key financial highlights from Humacyte, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for HUMAW?
The investment thesis for HUMAW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Humacyte, Inc.?
Key executives identified across Humacyte, Inc.'s filings include Laura E. Niklason, Brady W. Dougan, John P. Bamforth, Emery N. Brown, Michael T. Constantino and 2 others.
What are the main risk factors for Humacyte, Inc. stock?
Of HUMAW's 39 assessed filings, 4 were flagged high-risk, 19 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Humacyte, Inc.?
Forward guidance and predictions for Humacyte, Inc. are extracted from SEC filings as they are enriched.